ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

REdI 2024 | D1S08 - Diversity in Clinical Trials: Drug Trials Snapshots Perspective

Автор: U.S. Food and Drug Administration

Загружено: 2025-09-12

Просмотров: 175

Описание: This presentation emphasized the importance of increasing diversity in clinical studies and outlined FDA's initiative to enhance diversity in drug development programs. The session provided an overview of Drug Trials Snapshots and explained how this tool supports transparency in clinical trial demographics. Key strategies for promoting diversity in clinical trials were discussed from the Drug Trials Snapshots perspective to improve representation in pharmaceutical research.

Timestamps

00:49 – Why it is important to Increase Diversity in Clinical Studies

01:31 – Statutory Requirements to Increase Diversity in Drug Development

04:44 – Drug Trials Snapshots (DTS)

17:18 – Summary

18:16 – Questions

Speakers:

Aden S. Asefa, MPH
Drug Trials Snapshot Lead
Office of Drug Evaluation Sciences (ODES)
Office of New Drugs (OND)
Center for Drug Evaluation and Research (CDER) | FDA

Learn more at: https://www.fda.gov/drugs/news-events...

-----------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2024 Playlist -    • 2024 CDER Small Business and Industry Assi...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]
Phone - (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
REdI 2024 | D1S08 - Diversity in Clinical Trials: Drug Trials Snapshots Perspective

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

REdI 2024 | D1S09 - Combination Products: Updates and Best Practices

REdI 2024 | D1S09 - Combination Products: Updates and Best Practices

FDA Clinical Investigator Training Course (CITC) 2022, Day 1 – Part 1

FDA Clinical Investigator Training Course (CITC) 2022, Day 1 – Part 1

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

CITC 2024 – D1S02 – Basics of Clinical Trial Design

CITC 2024 – D1S02 – Basics of Clinical Trial Design

REdI 2024 | D1S07 - ClinicalTrials.gov: Meeting Transparency and Reporting Requirements

REdI 2024 | D1S07 - ClinicalTrials.gov: Meeting Transparency and Reporting Requirements

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

REdI 2024 | D1S05 - The CDER Center for Clinical Trial Innovation (C3TI)

REdI 2024 | D1S05 - The CDER Center for Clinical Trial Innovation (C3TI)

2024 CDER Small Business and Industry Assistance Webinars and Conferences

2024 CDER Small Business and Industry Assistance Webinars and Conferences

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Roundtable on PMTA Submissions for ENDS Products

Roundtable on PMTA Submissions for ENDS Products

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

CITC 2024 – D3S08 – Q&A Discussion Panel 2

CITC 2024 – D3S08 – Q&A Discussion Panel 2

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]